Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 14/20 | 0.69 |
| ▸ | JAK2 | O60674 | 3/20 | 0.53 |
| ▸ | JAK1 | P23458 | 3/20 | 0.53 |
| ▸ | TYK2 | P29597 | 3/20 | 0.53 |
| ▸ | JAK3 | P52333 | 3/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.40 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241242 | 1.00 | TDP1 (0.69) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL241840 | 0.94 | TDP1 (0.62) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL12522967 | 0.94 | TDP1 (0.75) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL3721877 | 0.93 | TDP1 (0.61) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL3728817 | 0.92 | TDP1 (0.60) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL13257263 | 0.92 | TDP1 (0.58) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL3720038 | 0.91 | TDP1 (0.59) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL27297353 | 0.91 | TDP1 (0.58) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL241362 | 0.90 | TDP1 (0.57) | TDP1JAK2JAK1TYK2JAK3 | |
| SCHEMBL3722720 | 0.90 | TDP1 (0.58) | TDP1JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | PHARMACOSMOS HOLDING A/S (KR) | 2026-03-03 | — | — | US | disclosed |
| EP-4684806-A1 | FAP-TARGETED ANTIBODY-DRUG CONJUGATES | Oncomatryx Biopharma, S.L. (ES) | 2026-01-28 | — | — | EP | disclosed |
| US-12527798-B2 | Preservation of immune response during chemotherapy regimens | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-20 | — | — | US | disclosed |
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-15 | — | — | US | disclosed |
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4652997-A2 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | Pharmacosmos Holding A/s (DK) | 2025-11-26 | — | — | EP | disclosed |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12433888-B1 | Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor | ACRIVON THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4153597-B1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | PHARMACOSMOS HOLDING AS (DK) | 2025-09-10 | — | — | EP | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-11529352-B2 | Preservation of immune response during chemotherapy regimens | G1 THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220306644-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220288404-A1 | METHODS FOR APPLYING TUMOR TREATING FIELDS IN COMBINATION WITH CANCER TREATING THERAPEUTICS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022192719-A2 | METHODS FOR APPLYING TUMOR TREATING FIELDS IN COMBINATION WITH CANCER TREATING THERAPEUTICS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| US-11357779-B2 | G1T38 superior dosage regimes | G1 THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | PHARMACOSMOS A/S (DK) | 2022-06-09 | — | — | US | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | CDK4, CCND1, CDK8 | TDP1 2234/4885JAK2 505/4885JAK1 455/4885 |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | TDP1 2371/4885JAK2 4085/4885JAK1 3541/4885 |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | RB1, CDK4, CDK6 | TDP1 131/4885JAK2 1760/4885JAK1 2584/4885 |
| US-11529352-B2 | Preservation of immune response during chemotherapy regimens | CDK6, CDKL4, CDK4 | TDP1 1047/4885JAK2 696/4885JAK1 293/4885 |
| US-12433888-B1 | Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor | CHEK1, WEE1, WEE2 | TDP1 134/4885JAK2 2167/4885JAK1 1402/4885 |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CCNO, CDK2, CCNI | TDP1 3177/4885JAK2 1003/4885JAK1 1018/4885 |
| US-20220306644-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | CDK2, CDK1, CCNK | TDP1 2145/4885JAK2 293/4885JAK1 373/4885 |
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | CHEK1, CHEK2, CKS1B | TDP1 413/4885JAK2 2821/4885JAK1 2083/4885 |
| US-11357779-B2 | G1T38 superior dosage regimes | CXCL8, ELANE, CD4 | TDP1 1699/4885JAK2 4018/4885JAK1 4524/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | TDP1 1541/4885JAK2 276/4885JAK1 278/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | TDP1 232/4885JAK2 534/4885JAK1 421/4885 |
| US-12527798-B2 | Preservation of immune response during chemotherapy regimens | CDK6, CDK4, CDKL4 | TDP1 869/4885JAK2 203/4885JAK1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.